ENROLLMENT WITH EVIDENCE-BASED APPROACHES ... Covance Inc., headquartered in Princeton, NJ, USA is the drug development
RHEUMATOID ARTHRITIS TREATMENT LANDSCAPE
Overcome Your Pain Points With an Experienced and Trusted Partner THERE REMAINS SIGNIFICANT UNMET NEED IN RA There is no cure
Biologic administration is often inconvenient and expensive
Safety of RA treatments, particularly immunosuppressive drugs, is still a concern
RA INDUSTRY UPDATES A trend towards more aggressive treatment under the "treat to target" strategy Steady market growth due in part to aging population
Movement towards early diagnosis and treatment of patients
Expanded range of treatment options including novel biologics and small molecules
Increasing availability of biosimilars making biologic treatments more accessible Biosimilars to infliximab, etanercept and adalimumab all approved
RA DRUG DEVELOPMENT PAIN POINTS Increasing demand for patients due to a small percentage participating in trials Difficulty in identifying investigators and locating patients Inefficient trial design, eligibility creep and inconsistencies in both subjective and objective trial outcomes Suboptimal patient retention over long trial periods Competitive biologics marketplace
COVANCE DRUG DEVELOPMENT SOLUTIONS
Addressing the Pain Points of RA Drug Development
OPTIMIZE STUDY PLANNING AND SPEED PATIENT ENROLLMENT WITH EVIDENCE-BASED APPROACHES Total of >175,000
clinical investigators
Total of >793,000 physicians
Total of >15 billion lab test results
Total of >16,000 protocols
Clinical knowledgebase housing >40% global clinical trial data at any one time TARGET PATIENT POPULATIONS FOR EFFICIENT RECRUITMENT Clinical trial opt-in patient initiative* currently with >2,572 RA patients Performance metrics on >1400 Ph II–III RA investigators since 2012 All RA study recruitment timelines achieved since 2012 Specialty inflammatory biomarkers, e.g., GlycA, rheumatoid factor and hCRP *Database of patients that have agreed to be contacted directly about relevant clinical trials